Loading...
Docoh

Synthetic Biologics (SYN)

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Company profile

Ticker
SYN
Exchange
CEO
Steven Shallcross
Employees
Incorporated
Location
Fiscal year end
Former names
ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC
SEC CIK
Subsidiaries
Pipex Therapeutics, Inc. • Effective Pharmaceuticals, Inc. • Solovax, Inc. • CD4 Biosciences, Inc. • Epitope Pharmaceuticals, Inc. • Healthmine, Inc. • Putney Drug Corp. • Synthetic Biomics, Inc. • VCN Biosciences, S.L. ...
IRS number
133808303

SYN stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 52.36M 52.36M 52.36M 52.36M 52.36M 52.36M
Cash burn (monthly) 1.48M 1.83M 1.66M 1.48M 1.45M 1.35M
Cash used (since last report) 2.15M 2.66M 2.42M 2.16M 2.11M 1.97M
Cash remaining 50.21M 49.7M 49.94M 50.21M 50.25M 50.39M
Runway (months of cash) 34.0 27.2 30.1 33.9 34.6 37.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Dec 21 Kraws Jeffrey J Stock Options Common Stock Grant Acquire A No No 0.3314 200,000 66.28K 200,000
23 Dec 21 John J Monahan Stock Options Common Stock Grant Acquire A No No 0.3314 200,000 66.28K 200,000
23 Dec 21 Steven A Shallcross Stock Options Common Stock Grant Acquire A No No 0.3314 650,000 215.41K 650,000
23 Dec 21 Wolf Jeffrey Alan Stock Options Common Stock Grant Acquire A No No 0.3314 200,000 66.28K 200,000
89.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 36 4 +800.0%
Opened positions 33 2 +1550.0%
Closed positions 1 36 -97.2%
Increased positions 1 0 NEW
Reduced positions 0 1 EXIT
13F shares Current Prev Q Change
Total value 5.42M 2.93M +85.2%
Total shares 14.25M 5.76M +147.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Vanguard 5.3M $1.51M NEW
Custodian Ventures 2.22M $1.96M 0.0%
BLK Blackrock 1.89M $538K NEW
Geode Capital Management 1.13M $321K NEW
Iroquois Capital Management 908.2K $247K 0.0%
STT State Street 486.92K $139K NEW
NTRS Northern Trust 336.4K $96K NEW
VIRT Virtu Financial 306.48K $87K NEW
Jane Street 281.7K $80K NEW
Blair William & Co 257.59K $73K NEW
Largest transactions Shares Bought/sold Change
Vanguard 5.3M +5.3M NEW
Hudson Bay Capital Management 0 -2.61M EXIT
BLK Blackrock 1.89M +1.89M NEW
Geode Capital Management 1.13M +1.13M NEW
STT State Street 486.92K +486.92K NEW
NTRS Northern Trust 336.4K +336.4K NEW
VIRT Virtu Financial 306.48K +306.48K NEW
Jane Street 281.7K +281.7K NEW
Blair William & Co 257.59K +257.59K NEW
Two Sigma Investments 163.17K +163.17K NEW

Financial report summary

?
Risks
  • We expect to seek to raise additional capital in the future, which may be dilutive to stockholders or impose operational restrictions.
Management Discussion
  • General and administrative expenses increased to $1.5 million for the three months ended June 30, 2022, from $1.3 million for the three months ended June 30, 2021. This increase of 19% primarily comprised of increased consulting and legal costs related to the VCN acquisition, higher insurance costs, audit fees, and public relations expenses and VCN administrative expenses not included in prior year. The charge related to stock-based compensation expense was $86,000 for the three months ended June 30, 2022, compared to $83,000 the three months ended June 30, 2021.
  • Research and development expenses increased to $3.5 million for the three months ended June 30, 2022, from approximately $1.9 million for the three months ended June 30, 2021. This increase of 80% is primarily the result of VCN research expenses related to VCN-01 not incurred in the prior year and to a lesser extent higher manufacturing expense for SYN-020, costs incurred related to our Phase 1a clinical trial of SYN-020 and expenses related to our Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense to increase as we plan for and initiate enrollment for our phase 2 clinical trial for VCN-01 in PDAC, phase 2/3 clinical trial in retinoblastoma, expand GMP manufacturing activities for VCN-01, and continue with supporting our VCN-11 and other preclinical and discovery initiatives. The charge related to stock-based compensation expense was $27,000 for the three months ended June 30, 2022, compared to $19,000 related to stock-based compensation expense for the three months ended June 30, 2021.
  • Other income was $17,000 for the three months ended June 30, 2022 compared to other income of $2,000 for the three months ended June 30, 2021. Other income for the three months ended June 30, 2022 is primarily comprised of interest income of $26,000 offset by an exchange loss of $9,000. Other income for the three months ended June 30, 2021 is primarily comprised of interest income.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: alter, automatically, chimeric, doi, downturn, Enterobacteriaceae, evenly, fat, gain, German, lesser, Master, MSD, nearest, notified, persisted, persistent, personnel, proportionate, proportionately, proxy, ratio, receptor, retrospectively, SPA, tropism, valuable, vendor
Removed: enterococci, exceed, fifty, halting, permitting, Plant, submission

Patents

Utility
Alkaline Phosphatase Agents for Treatment of Neurodevelopmental Disorders
4 Aug 22
The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
Utility
Beta-lactamase Compositions for Treatment of Graft Versus Host Disease
14 Jul 22
The present invention relates to, in part, methods and compositions for reducing the incidence and/or severity of complications associated with IV beta-lactam antibiotic use in allo-HCT recipients, such as aGVHD and VRE colonization and/or VRE bloodstream infection, using beta-lactamase agents.
Utility
Alkaline Phosphate-based Oncology Treatments
30 Jun 22
The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).
Utility
Alkaline phosphatase agents for treatment of neurodevelopmental disorders
24 May 22
Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.
Utility
Safe and Effective Beta-lactamase Dosing for Microbiome Protection
28 Apr 22
The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.